Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Castration-Resistant Prostatic Cancer
Interventions
[Lu-177]-PNT2002
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
U.S. locations
7
States / cities
Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
Fractionated dose of 225Ac-J591, 68Ga-PSMA-HBED-CC injection, Multiple single doses of 225Ac-J591
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
AAA617, 68Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Metastatic Progressive Castration-resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
Abiraterone, ABT-263, Hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Interventions
enzalutamide, CRLX101
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
Interventions
Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Denver, Colorado • Jacksonville, Florida • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib
Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11, 177Lu-PSMA-I&T
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • New Brunswick, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
ARN-509 (Phase 1), ARN-509 (Phase 2)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Metastatic Prostate Cancer
Interventions
177Lu-CYT-500
Drug
Lead sponsor
Cytogen Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2007 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
177Lu-PSMA-617, Best supportive/best standard of care
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
45
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
Interventions
Recombinant EphB4-HSA Fusion Protein
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostatic Neoplasms
Interventions
Prednisone, sunitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Decatur, Alabama • Huntsville, Alabama • Anaheim, California + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
apalutamide, Everolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 22, 2026, 4:11 AM EDT
Conditions
Prostate Cancer
Interventions
chemotherapy, tipifarnib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced May 22, 2026, 4:11 AM EDT